Paratek Pharmaceuticals (FRA:N4CN) Net Issuance of Preferred Stock : €0.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Paratek Pharmaceuticals's net issuance of preferred for the three months ended in Jun. 2023 was €0.0 Mil. The number is 0, which means that Paratek Pharmaceuticals has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Paratek Pharmaceuticals's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was €0.0 Mil.

Paratek Pharmaceuticals Net Issuance of Preferred Stock Historical Data

The historical data trend for Paratek Pharmaceuticals's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Net Issuance of Preferred Stock Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Paratek Pharmaceuticals Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Paratek Pharmaceuticals Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines